The second group with decreased PQR620 sensitivity was represented by mutated DLBCL cell lines bearing an inactive TP53. The contribution of TP53 in the response to mTOR inhibitors is not defined, but it is certainly relevant in particular conditions [24,42,43]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.